Phase 3 GAN Clinical Trials

23 recruitingPhase 3

What is a Phase 3 trial?

Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.

Showing 120 of 23 trials

Recruiting
Phase 3

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
National Cancer Institute (NCI)1,875 enrolled407 locationsNCT05675410
Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled251 locationsNCT06935357
Recruiting
Phase 3

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NeuroblastomaGanglioneuroblastoma, Nodular
National Cancer Institute (NCI)478 enrolled178 locationsNCT06172296
Recruiting
Phase 3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

IgA NephropathyImmunoglobulin A NephropathyBerger Disease+3 more
Novartis Pharmaceuticals28 enrolled6 locationsNCT07498335
Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

GM1 GangliosidosisGM2 GangliosidosisNiemann-Pick Type C Disease
Azafaros B.V.147 enrolled38 locationsNCT07054515
Recruiting
Phase 3

A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis

Gangliosidoses, GM2Gangliosidosis, GM1
Azafaros B.V.75 enrolled36 locationsNCT07082543
Recruiting
Phase 3

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Pyoderma Gangrenosum
Boehringer Ingelheim90 enrolled98 locationsNCT06624670
Recruiting
Phase 2Phase 3

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

Rectal Cancer Stage IIIRectal Cancer PatientsOrgan Preservation+2 more
Sir Mortimer B. Davis - Jewish General Hospital131 enrolled4 locationsNCT03051464
Recruiting
Phase 3

Tacrolimus Minimization in Kidney Transplant Recipients Selected According to the AGORA Algorithm for Their Low Immunological Risk and Medium-term Graft Failure

Organ Grafts
Nantes University Hospital300 enrolled3 locationsNCT06235892
Recruiting
Phase 3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled17 locationsNCT06994845
Recruiting
Phase 3

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled9 locationsNCT07390123
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 2Phase 3

Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.

Radiotherapy Side EffectNeoadjuvant TherapyChemotherapy+8 more
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos400 enrolled1 locationNCT06758830
Recruiting
Phase 3

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Phase 3

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Phase 2Phase 3

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Nationwide Children's Hospital500 enrolled32 locationsNCT05267821
Recruiting
Phase 3

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NeuroblastomaGanglioneuroblastoma, NodularGanglioneuroblastoma
Children's Oncology Group750 enrolled162 locationsNCT03126916
Recruiting
Phase 3

Anesthesia sTrategy foR Organ Procurement In braiN dEath

Brain-dead Organ Donors
University Hospital, Grenoble270 enrolled1 locationNCT07166991
Recruiting
Phase 3

Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

Neuroblastoma (NB)Ganglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology5 enrolled1 locationNCT07375563
Recruiting
Phase 3

A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria

IgA Nephropathy (IgAN)
Biocity Biopharmaceutics Co., Ltd.360 enrolled1 locationNCT06819826